SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

WHI-P154

Item No. 16178

CAS Registry No.:	211555-04-3
Formal Name:	2-bromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]-phenol
Synonyms:	JAK3 Inhibitor II, Janus-Associated Kinase 3 Inhibitor II
MF:	$C_{16}H_{14}BrN_3O_3$
FW:	376.2
Purity:	≥98%
UV/Vis.:	λ_{max}: 228, 247, 335 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

WHI-P154 is supplied as a crystalline solid. A stock solution may be made by dissolving the WHI-P154 in the solvent of choice, which should be purged with an inert gas. WHI-P154 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of WHI-P154 in these solvents is approximately 15 and 25 mg/ml, respectively.

WHI-P154 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, WHI-P154 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. WHI-P154 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

WHI-P154 is a quinazoline derivative that exhibits immunosuppressive effects by selectively inhibiting JAK3 (IC_{50} = 1.8 µM *versus* IC_{50}s > 10 µM for JAK1 and JAK2).[1] It has been reported to inhibit additional kinases including EGFR (IC_{50} = 4 nM) and VEGFR as well as the non-receptor tyrosine kinases, Abl, Lck, and Src.{26468} WHI-P154 is cytotoxic to human glioblastoma cells (IC_{50} = 813 nM) and has been used to induce the differentiation of neuronal precursor cells.[2-4]

References

1. Changelian, P.S., Moshinsky, D., Kuhn, C.F., *et al.* The specificity of JAK3 kinase inhibitors. *Blood* **111(4)**, 2155-2157 (2008).
2. Narla, R.K., Liu, X.-P., Myers, D.E., *et al.* 4-(3'-Bromo-4'hydroxylphenyl)-amino-6,7-dimethoxyquinazoline: A novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells. *Clin. Cancer Res.* **4(6)**, 1405-1414 (1998).
3. Narla, R.K., Liu, X.-P., Klis, D., *et al.* Inhibition of human glioblastoma cell adhesion and invasion by 4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) and 4-(3'-bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P154). *Clin. Cancer Res.* **4(10)**, 2463-2471 (1998).
4. Kim, Y.H., Chung, J.-I., Woo, H.G., *et al.* Differential regulation of proliferation and differentiation in neural precursor cells by the Jak pathway. *Stem Cells* **28(10)**, 1816-1828 (2010).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM